Adoption of Non-commercial Studies
1.1 What type of research can DeNDRoN support?
DeNDRoN supports the conduct of randomised controlled trials and other well designed studies, including those for prevention, diagnosis and treatment. This includes fully funded commercial and non-commercial trials, which are conducted for patient benefit and address key issues arising from the disease, which affect the patient or carer.
DeNDRoN can facilitate:
· both observational or interventional studies
· single centre and multi-centre research
1.2 How does a study qualify for DeNDRoN support?
It is expected that all high quality research that involves NHS patients and/or resources, and that is funded by the NIHR and its Partners, will be included in the UKCRN Portfolio in order to access service support costs. In future the portfolio will replace the National Research Register and track all quality research, funded in open national competition throughout the UK.
All Studies funded by industry or non-NIHR partners will be adopted into the portfolio, based upon UK study feasibility and LRN capability.
1.3 Definition of an NIHR partner
NIHR Partners are those organisations that:
a) award research funds as a result of open competition across England with high quality peer review
b) fund research that is of clear value to the NHS
c) have strategic direction for the research that they fund
This includes medical charities, large funding bodies and all UKCRC collaborators
1.4 Submission of portfolio adoption documents
A DeNDRoN portfolio submission form and protocol must be sent to the co-ordinating centre at the point of funding, for review by an adoption panel. The form is easy to complete and captures the minimum dataset required to populate the UKCRN portfolio database. Details of any pre-selected sites should also be submitted to allow LRN managers to make contact, offer support and determine the level required.
Each LRN will be able to choose which studies are included in its local portfolio, however trials must be adopted into the UKCRN portfolio to be eligible for DeNDRoN LRN support.